Market: NASD |
Currency: USD
Address: 4224 Campus Point Court
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
📈 Regulus Therapeutics Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.00
-
Upside/Downside from Analyst Target:
-14.22%
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2022 |
- |
$0.100000 |
- |
2022-06-29 |
- |
Stock split |
|
Total Amount for 2022: $0.100000 |
| 2018 |
- |
$0.083333 |
- |
2018-10-04 |
- |
Stock split |
|
Total Amount for 2018: $0.083333 |
📅 Earnings & EPS History for Regulus Therapeutics Inc.
| Date | Reported EPS |
|---|
| 2025-08-07 | - |
| 2025-05-08 | -0.15 |
| 2025-03-13 | -0.2 |
| 2024-11-07 | -0.21 |
| 2024-08-08 | -0.17 |
| 2024-05-09 | -0.29 |
| 2024-03-21 | -0.4 |
| 2023-11-09 | -0.4 |
| 2023-08-08 | -0.37 |
| 2023-05-11 | -0.42 |
| 2023-03-23 | -0.4 |
| 2022-11-10 | -0.5 |
| 2022-08-11 | -0.5 |
| 2022-05-12 | -0.5 |
| 2022-03-10 | -0.7 |
| 2021-11-10 | -1 |
| 2021-08-10 | -0.8 |
| 2021-05-13 | -0.8 |
| 2021-03-09 | -0.3 |
| 2020-11-05 | -0.4 |
| 2020-08-13 | -2.3 |
| 2020-05-14 | -2.5 |
| 2020-03-12 | -2.3 |
| 2019-11-12 | -2.6 |
| 2019-08-08 | -3 |
📰 Related News & Research
No related articles found for "regulus therapeutics".
